CLINICAL TRIALS PROFILE FOR ENTINOSTAT
✉ Email this page to a colleague
Clinical Trials for Entinostat
Trial ID | Title | Status | Sponsor | Phase | Summary |
---|---|---|---|---|---|
NCT00015925 ↗ | MS-275 in Treating Patients With Hematologic Cancer | Completed | National Cancer Institute (NCI) | Phase 1 | RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of MS-275 in treating patients who have hematologic cancer. |
NCT00015925 ↗ | MS-275 in Treating Patients With Hematologic Cancer | Completed | Sidney Kimmel Comprehensive Cancer Center | Phase 1 | RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of MS-275 in treating patients who have hematologic cancer. |
NCT00015925 ↗ | MS-275 in Treating Patients With Hematologic Cancer | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1 | RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of MS-275 in treating patients who have hematologic cancer. |
NCT00020579 ↗ | MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma | Completed | National Cancer Institute (NCI) | Phase 1 | RATIONALE: MS-275 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: This phase I trial is studying the side effects and best dose of MS-275 in treating patients with advanced solid tumors or lymphoma. |
NCT00020579 ↗ | MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma | Completed | National Institutes of Health Clinical Center (CC) | Phase 1 | RATIONALE: MS-275 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: This phase I trial is studying the side effects and best dose of MS-275 in treating patients with advanced solid tumors or lymphoma. |
NCT00098891 ↗ | MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas | Completed | National Cancer Institute (NCI) | Phase 1 | Phase I trial to study the effectiveness of combining MS-275 with isotretinoin in treating patients who have metastatic or advanced solid tumors or lymphomas. MS-275 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. Isotretinoin may help cancer cells develop into normal cells. MS-275 may increase the effectiveness of isotretinoin by making cancer cells more sensitive to the drug. MS-275 and isotretinoin may also stop the growth of solid tumors or lymphomas by stopping blood flow to the cancer. Combining MS-275 with isotretinoin may kill more cancer cells |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Entinostat
Condition Name
Clinical Trial Locations for Entinostat
Trials by Country
Clinical Trial Progress for Entinostat
Clinical Trial Phase
Clinical Trial Sponsors for Entinostat
Sponsor Name